Paul Bevan - Publications

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Journal: JAMA oncology

Published: October 28, 2016

Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.

Journal: Cancer chemotherapy and pharmacology

Published: June 02, 2016

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 30, 2016

Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma.

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Published: March 15, 2016

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial.

Journal: Urologic oncology

Published: January 18, 2015

Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.

Journal: International journal of oncology

Published: July 09, 2014

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.

Journal: British journal of cancer

Published: February 16, 2013

Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 06, 2012